Flagship Harbor Advisors LLC Sells 506 Shares of IDEXX Laboratories, Inc. $IDXX

Flagship Harbor Advisors LLC reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,480 shares of the company’s stock after selling 506 shares during the period. Flagship Harbor Advisors LLC’s holdings in IDEXX Laboratories were worth $1,330,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in IDXX. Mather Group LLC. increased its position in IDEXX Laboratories by 76.3% in the 1st quarter. Mather Group LLC. now owns 760 shares of the company’s stock worth $319,000 after buying an additional 329 shares during the period. Summit Trail Advisors LLC grew its holdings in shares of IDEXX Laboratories by 53.2% during the 1st quarter. Summit Trail Advisors LLC now owns 1,241 shares of the company’s stock worth $521,000 after purchasing an additional 431 shares in the last quarter. DAVENPORT & Co LLC grew its holdings in shares of IDEXX Laboratories by 20.2% during the 1st quarter. DAVENPORT & Co LLC now owns 6,793 shares of the company’s stock worth $2,853,000 after purchasing an additional 1,140 shares in the last quarter. Keybank National Association OH grew its holdings in shares of IDEXX Laboratories by 7.8% during the 1st quarter. Keybank National Association OH now owns 4,061 shares of the company’s stock worth $1,705,000 after purchasing an additional 294 shares in the last quarter. Finally, Private Trust Co. NA grew its holdings in shares of IDEXX Laboratories by 21.2% during the 1st quarter. Private Trust Co. NA now owns 240 shares of the company’s stock worth $101,000 after purchasing an additional 42 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $628.54 on Friday. The stock’s fifty day simple moving average is $638.21 and its 200 day simple moving average is $565.90. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The firm has a market cap of $50.28 billion, a price-to-earnings ratio of 52.33, a P/E/G ratio of 4.06 and a beta of 1.58. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IDXX. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a report on Monday, August 4th. UBS Group began coverage on IDEXX Laboratories in a report on Wednesday, October 1st. They set a “neutral” rating and a $720.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an “overweight” rating in a report on Monday, August 4th. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $656.50.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the business’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the transaction, the executive vice president owned 7,132 shares of the company’s stock, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares in the company, valued at approximately $169,600.46. This represents a 89.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 54,057 shares of company stock valued at $34,293,468. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.